CERE News and Press, Ceres Inc. From 08/04/23

2023-08-04 13:26:12 ET Summary Cerevel Therapeutics Holdings, Inc. experienced a drop in shares due to a delay in releasing top-line results from studies on emraclidine for schizophrenia treatment. Emraclidine is also being developed for Alzheimer's Disease Psychosis, with a phase...

2023-08-03 11:14:47 ET More on Cerevel Cerevel Therapeutics Holdings, Inc. ( CERE ) Q2 2023 Earnings Call Transcript Cerevel: High Priced Stock Doing Interesting Science Pfizer spinout Cerevel names Bain Capital partner Ron Renaud as new CEO Cerevel Thera...

2023-08-02 13:42:49 ET More on Cerevel Cerevel Therapeutics Holdings, Inc. ( CERE ) Q2 2023 Earnings Call Transcript Cerevel: High Priced Stock Doing Interesting Science Pfizer spinout Cerevel names Bain Capital partner Ron Renaud as new CEO Cerevel exten...

2023-08-02 12:56:07 ET Cerevel Therapeutics Holdings, Inc. (CERE) Q2 2023 Results Conference Call August 02, 2023 08:00 AM ET Company Participants Matthew Calistri - Vice President of Investor Relations Ron Renaud - President and Chief Executive Officer Raymond S...

2023-08-02 10:47:55 ET Shares of Cerevel Therapeutics (NASDAQ: CERE) were down more than 14% as of 10:30 a.m. ET on Wednesday after the healthcare company reported second-quarter earnings. The stock is down more than 17% so far this year. Cerevel focuses on therapies to treat ne...

2023-08-02 10:17:25 ET Gainers: TRxADE HEALTH ( MEDS ) +60% . Armata Pharmaceuticals ( ARMP ) +17% . Teva Pharmaceutical Industries ( TEVA ) +13% . CareDx ( CDNA ) +9% . Mallinckrodt ( MNK ) +9% . Losers: Adamis Pharmaceut...

2023-08-02 06:41:53 ET Cerevel Therapeutics press release ( NASDAQ: CERE ): Q2 GAAP EPS of -$0.63 beats by $0.06 . Cash, cash equivalents, and marketable securities of $825.1 million as of June 30, 2023, expected to support a data-rich 2024 and fund operations into 202...

Three new executives added to leadership team: Ron Renaud, Susan Altschuller, Paul Burgess Emraclidine EMPOWER data now expected second half 2024 Darigabat ADAPT trial in panic disorder initiated Cash, cash equivalents, and marketable securities of $825.1 million as of Jun...

CAMBRIDGE, Mass., July 05, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report second quarter 2023 financial results and business updates on Wed...

Mr. Burgess will be responsible for leading Cerevel’s business development and quality teams Mr. Burgess to join Cerevel effective June 20, 2023 CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling th...